NKTR-255 with CD19 chimeric antigen receptor T-cell therapy improved 6-month complete response rates in relapsed/refractory large B-cell lymphoma. The combination of NKTR-255 with CD19-directed ...

Bispecific antibodies offer an off-the-shelf alternative to the autologous chimeric antigen receptor (CAR) T cell platform and often outcompete CAR T cells due to their ease of use, and the ability to ...

982402) anti-human CD19 (HIB19), purified (cat.303202) and APC-conjugated (cat ... Alexa 568 goat anti-mouse (cat.A21124), Alexa 568-Streptavidin (cat.S11226), and Alexa 568 goat anti-rat (cat.A11077) ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies. Now, it has bolted on a bispecific via a $1.3 billion licensing deal with Curon Biopharma. The big ...

Q4 2024 Earnings Call Transcript February 10, 2025 Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and ...

Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate the business. The company had been planned to secure permission from ...

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...